1. Home
  2. CDP vs CELC Comparison

CDP vs CELC Comparison

Compare CDP & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo COPT Defense Properties of Beneficial Interest

CDP

COPT Defense Properties of Beneficial Interest

HOLD

Current Price

$29.63

Market Cap

3.2B

Sector

Real Estate

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$106.44

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDP
CELC
Founded
1988
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical Specialities
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.1B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
CDP
CELC
Price
$29.63
$106.44
Analyst Decision
Buy
Strong Buy
Analyst Count
7
8
Target Price
$33.29
$100.13
AVG Volume (30 Days)
882.8K
874.9K
Earning Date
10-30-2025
11-12-2025
Dividend Yield
4.11%
N/A
EPS Growth
9.45
N/A
EPS
1.32
N/A
Revenue
$752,757,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.48
N/A
P/E Ratio
$22.46
N/A
Revenue Growth
0.43
N/A
52 Week Low
$23.92
$7.58
52 Week High
$33.49
$107.04

Technical Indicators

Market Signals
Indicator
CDP
CELC
Relative Strength Index (RSI) 51.80 78.81
Support Level $29.59 $96.70
Resistance Level $30.99 $102.58
Average True Range (ATR) 0.58 5.73
MACD -0.02 -0.06
Stochastic Oscillator 46.85 98.67

Price Performance

Historical Comparison
CDP
CELC

About CDP COPT Defense Properties of Beneficial Interest

COPT Defense Properties is a fully-integrated and self-managed real estate investment trust (REIT) focused on owning, operating and developing properties in locations proximate to, or sometimes containing, key U.S. Government (USG) defense installations and missions. Its tenants include the USG and their defense contractors, who are engaged in priority national security activities, and who generally require mission-critical and high security property enhancements. Its properties include 195 operating properties totaling approximately 22.4 million square feet comprised of 16.5 million square feet in 164 office properties and 5.9 million square feet in 31 single-tenant data center shells.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: